• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, June 26, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home Headlines

TTUHSC researcher receives NIH grant for vaccine

Bioengineer.org by Bioengineer.org
January 20, 2018
in Headlines, Health, Science News
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram
IMAGE

IMAGE: Dr. Afzal A. Siddiqui received $3.82 million NIH grant for vaccine.

Credit: TTUHSC

Texas Tech University Health Sciences Center (TTUHSC) researcher Afzal A. Siddiqui, Ph.D., a Grover E. Murray Distinguished Professor at the TTUHSC School of Medicine, received a $3.82 million grant from the National Institutes of Health (NIH). The three-year NIAID/SBIR-R44 Phase II Grant is to prepare the Schistosomiasis Vaccine (SchistoShield®) for human clinical trials. This phase of the research funding is in collaboration with Darrick Carter, president and CEO of PAI Life Science in Seattle, WA.

Over 200 million people suffer from the disease in 74 countries and four times that many are at risk since they do not have access to clean water. A recent discovery in Siddiqui's TTUHSC research laboratory may make it possible to reduce the number of infections from this disease.

According to the World Health Organization, there are no commercially available vaccines against schistosomiasis, which afflicts people primarily in Asia, Africa and South America.

A person gets a schistosoma infection through contact with contaminated water. The
parasite swims freely in open bodies of water. Once contact is made with humans, the parasite burrows into the skin, matures into another stage, and then migrates to the lungs and liver, where it matures into the adult form.

"Dr. Siddiqui is the quintessential investigator and has brought distinction not only to this research but to our university," said TTUHSC President Tedd L. Mitchell, M.D. "We are extremely proud of his work and congratulate him on this NIH grant."

The vaccine, "SchistoShield®" potentially can impact up to one billion people.
Siddiqui also recently received a U.S. patent for the schistosomiasis vaccine. With this NIH grant and an ongoing Bill & Melinda Gates Foundation grant, Siddiqui's research team has over $7 million in current grant funding and over $11.5 million in total funding thus far on this project.

###

Media Contact

Suzanna Cisneros
[email protected]
806-743-7605
@ttuhsc

http://www.ttuhsc.edu

Share12Tweet8Share2ShareShareShare2

Related Posts

Tracking Lanthanide-Labeled Microplastics in Plants

June 25, 2026

POSTECH Researchers Slash Cost of Reconstituted Cell-Free Systems by 95%

June 25, 2026

AI and Physics Collaborate to Design Advanced Hydrogen Storage Materials

June 25, 2026

Natural Hallucinogens: Evolution’s Ecological Tools, Not Mere Chemical Byproducts

June 25, 2026
Please login to join discussion

POPULAR NEWS

  • Saying Goodbye to PGY-6: Pediatric Fellowship Realities

    103 shares
    Share 41 Tweet 26
  • Multi-Hospital Study Reveals Long Covid Burden Is Twice as High as Current Estimates

    92 shares
    Share 36 Tweet 23
  • Detection of EDCs in Breast Milk and Infant Urine Up to Six Months Highlights Early Exposure Risks

    77 shares
    Share 31 Tweet 19
  • New Drug Candidate Developed at McMaster Shows Potential for Treating Brain Cancer

    58 shares
    Share 23 Tweet 15

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Tracking Lanthanide-Labeled Microplastics in Plants

POSTECH Researchers Slash Cost of Reconstituted Cell-Free Systems by 95%

AI and Physics Collaborate to Design Advanced Hydrogen Storage Materials

Subscribe to Blog via Email

Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm' to start subscribing.

Join 82 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.